

Antitumor Activity of Pedunculagin, one of the Ellagitannin

Jee Hun Chang¹, Jang Hyun Cho¹, Ha Hyung Kim¹, Kwang Pyo Lee¹, Min Won Lee², Seong Sun Han³ and Do Ik Lee¹

¹Division of Immunology, ²Division of Pharmacognosy, College of Pharmacy, Chung Ang University, Seoul 156-756, Korea and ³Division of Microbiology, College of Pharmacy, Chung Buk National University, Cheong Ju, Chung Buk 360-763, Korea

(Received November 10, 1994)

As a part of trials to develop the antitumor agent from tannins isolated from plants, the antitumor activity of pedunculagin, an ellagitannin, isolated from *Alnus hirsuta* var. *microphylla* was examined *in vitro* and *in vivo*. *In vitro*, the cytotoxicity was determined by 0.4% trypan blue dye exclusion method. Pedunculagin showed the dose-dependent cytotoxicity against human chronic myelogenous leukemia (K-562), human promyelocytic leukemia (HL-60), mouse lymphoid neoplasm (P388), mouse lymphocytic leukemia (L1210) and mouse sarcoma 180 (S 180) cell lines. ED₅₀ values (ED₅₀) of each cell line were 5.30, 0.92, 2.78, 9.35 and 1.38 µg/ml respectively. The most sensitive cell line was HL-60. *In vivo*, pedunculagin was administered to ICR mouse with the doses of 50 and 100 µg/kg intraperitoneally once at 20 days before S180 inoculation. Pedunculagin showed the antitumor activity and its T/C ratio (%) was 120.82% in the group of both concentrations.

Key Words : Pedunculagin, Antitumor activity, Ellagitannin, T/C ratio

INTRODUCTION

The surgical operation, radiological remedy, immunotherapy, medical therapy and so on have been applied in treating cancers. Due to its metastasis, it is difficult to suppress cancer cell growth with local treatment only. Therefore, systemic treatment-medical therapy has been carried out fundamentally at the same time (Gilman *et al.*, 1988; Dipiro *et al.*, 1989).

Recently, the studies of antitumor agents have been directed to make up for defects, such as drug delivery systems (Bodor *et al.*, 1987; Poste *et al.*, 1982; Mazer *et al.*, 1990) and prodrug-form (Anders *et al.*, 1987; Gogate *et al.*, 1987).

On the other hand, the efforts of developing antitumor agents from plants have been tried (Han *et al.*, 1991; Ahn *et al.*, 1992; Zahang *et al.*, 1980; Ikekawa *et al.*, 1968; Ikekawa *et al.*, 1969). So, effective antitumor agents were developed (Arai *et al.*, 1971; Torikai *et al.*, 1978) and their mechanisms were generally known (Yukio *et al.*, 1981; Maeda *et al.*, 1971; Bomford *et al.*, 1977; Komatsu *et al.*, 1969).

This study was scheduled and progressed with a

view to developing a new antitumor agent from tannins isolated from *Alnus hirsuta* var. *microphylla*.

Tannins are polyhydric phenols found in plants, and polymolecular substances linked with proteins and alkaloids (M.W. = 500~3,000). Tannins are classified chemically into hydrolyzable tannin and condensed tannin. Hydrolyzable tannin is classified furthermore into gallotannin in which only galloyl radical is combined with saccharide and ellagitannin which is metabolized to ellagic acid by hydrolysis (Lyu *et al.*, 1989).

Tannins are widely distributed in plants, and are significant to human because of their usage as tanning agents, dyes, and drugs in addition to their wide distribution as astringent components in many foodstuffs (Shirahata *et al.*, 1985), and reported to possess a variety of biological activities such as lowering effect of the blood urea nitrogen (Shibutai *et al.*, 1983), inhibiting effect of the activity of ACE (Inokuchi *et al.*, 1985; Uchida *et al.*, 1987), antiviral effect (Lee *et al.*, 1992; Nonaka *et al.*, 1990), DNA-breaking effect (Shirahata *et al.*, 1985; Shirahata *et al.*, 1989), psychotropic effect (Ueki *et al.*, 1986) and antibacterial effect (Serit *et al.*, 1991).

In the recent study, tannins were reported to have the antitumor activity (Yoshida *et al.*, 1991; Gali *et al.*, 1992; Yoshiki *et al.*, 1992; Miyamoto *et al.*, 1993a;

Correspondence to: Do Ik Lee, Division of Immunology, College of Pharmacy, Chung Ang University, 221 Huk Suk Dong, Dong Jak Gu, Seoul 156-756, Korea

Miyamoto *et al.*, 1993b; Miyamoto *et al.*, 1993c). Among them, Yoshiki *et al.* (1992) reported that 129 tannins and relative compounds showed the antitumor activity, but all of the tannins were found to be inactive ($ED_{50} > 10 \mu\text{g/ml}$) against A549, HCT-8, KB and TE671 cell lines.

Moreover, Miyamoto *et al.* (1993a) reported that ellagitannins showed IL-1 induction and that 21 ellagitannins had the antitumor activity in mouse bearing S180 (Miyamoto *et al.*, 1993b). In addition, ellagitannin was reported to have DNA breakage activity (Shirahata *et al.*, 1985) and pedunculagin was reported to have anti-HIV activity (Lee *et al.*, 1992).

In this paper, the direct cytotoxicity of pedunculagin, an ellagitannin, isolated from *Alnus hirsuta* var. *microphylla* against K-562, HL-60, P388, L1210 and S180 and the lengthening effect of the life span in mice bearing S180 were examined and discussed.

MATERIALS AND METHODS

Materials

Pedunculagin was isolated from *Alnus hirsuta* var. *microphylla*. Its structure is shown in Fig. 1. Fetal bovine serum (FBS) was obtained from Hyclone Co., Ltd. RPMI1640 media, trypan blue, dimethyl sulfoxide (DMSO) were purchased from Sigma Co., Ltd..

In vitro assay

Cell culture: K-562, HL-60, P388, L1210 and S180 cell lines were subcultured from Chong-Keun Dang Co., Ltd. and used. Cell lines were routinely maintained in the CO_2 incubator (95% air and 5% CO_2) at 37°C RPMI1640 medium supplemented with 10% heat-inactivated (56°C , 30 min.) FBS was used in this study. Cell lines were kept under LN_2 until use and used at early passage as possible.

Assay method: Four milliliters of cell suspension in logarithmic phase was inoculated into each well of 12 well plate, and treated with the concentrations of 1, 5, 10 and $20 \mu\text{g/ml}$ of pedunculagin. After treatment, cells were incubated for further 48 hours (hr). Living

cells were counted at each 24 and 48 hr on hemacytometer by 0.4% trypan blue dye exclusion method.

Data calculation: The value of ED_{50} which was the concentration of a test compound to inhibit the growth of tumor cells by 50% to control was determined with protocol of National Cancer Institute (NCI), USA (Thayer., 1971).

In vivo assay

Animal: ICR mice used for this study were purchased from Dae-Ryuk Co.. 3-week-old ICR mice were purchased. After raising for 1 week, ICR mice were used for the antitumor test. Male (20-25 g) ICR mice were divided into groups of 8 mice for each *in vivo* assay.

Tumors: S180 tumor cell line was kindly provided by Sun-Kyung Industrial Co. (SKI) where S180 had been maintained in the ascites form.

Treatment: Pedunculagin was prepared in sterile distilled water. Fifty and $100 \mu\text{g/kg}$ of pedunculagin were administered intraperitoneally once at 20 days before S180 inoculation. After 20 days of pedunculagin administration, 0.1 ml of washed S180 cells (10^6 cells/ml) was implanted in the peritoneal cavity of mice, and their life spans were examined and recorded.

Data calculation: ICR mice were examined for 30 days after S180 inoculation. Their life spans were recorded. At 30 days after S180 inoculation, survivors were divided into No-takes (Failure of individual implants) group and S180 bearing group. Mice divided into No-takes and mice that died within the 10th day were excluded from calculation by the protocol of NCI, USA (Cancer Chemotherapy National Service Center, 1972).

T/C ratio (%) was calculated with mean survival time (MST) computed according to the equation below (Hyun, 1993).

$$\text{T/C ratio (\%)} = \frac{\text{MST of Treated Group}}{\text{MST of Control Group}} \times 100$$

RESULTS AND DISCUSSION

In vitro

Pedunculagin was examined for the cytotoxicity on the growth of five cultured tumor cell lines.

Initial cell number of K-562 was 3.94×10^4 cells/ml, and its ED_{50} to pedunculagin was $5.30 \mu\text{g/ml}$ (Table I). Pedunculagin showed the dose-dependent cytotoxicity against K-562 (Fig. 2).

Initial cell number of HL-60 was 7.00×10^4 cells/ml, and its ED_{50} to pedunculagin was $0.92 \mu\text{g/ml}$ (Table I). Pedunculagin showed the significant cytotoxicities in all concentration at 48 hr (Growth ratio < 50%), but




Fig. 1. The structure of pedunculagin




Fig. 2. The effect of pedunculagin on the growth of K-562 cells. ○:control ●:1 µg/ml ▽:5 µg/ml ▼:10 µg/ml □:20 µg/ml, 3.95×10^5 cells/ml were cultured in 5% CO₂ incubator at 37°C for 48 hr, a vs b and e vs f: $p < 0.05$, a vs c, d and e vs g, h, i: $p < 0.01$ (Student's t-test), The values were given as Mean ± S.E. of n=4.




Fig. 3. The effect of pedunculagin on the growth of HL-60 cells. ○:control ●:1 µg/ml ▽:5 µg/ml ▼:10µg/ml □:20 µg/ml, 7.00×10^5 cells/ml were cultured in 5% CO₂ incubator at 37°C for 48 hr, a vs b, c, d, e and f vs g, h, i, j: $p < 0.01$ (Student's t-test). The values were given as Mean ± S.E. of n=4.

Table I. The cytotoxicity of pedunculagin on growth of cell lines

Cell Lines	Growth ratio ^a (%) at different concentrations (µg/ml)				ED ₅₀ ^b (µg/ml)	
	Control	1	5	10		20
HL-60	100	46.67	37.22	13.33	12.22	0.92
K-562	100	77.11	53.57	36.65	28.69	5.30
L-1210	100	78.42	55.70	50.40	40.74	9.35
P388	100	68.13	40.79	33.21	-4.23	2.78
S-180	100	62.50	9.45	1.83	-7.01	1.38

$$a: Y(\%) = \frac{T-Co}{C-Co} \times 100$$

Y: growth ratio for each dose of testing substances

T: mean cell count for each dose of testing substances after 48 hr incubation

C: mean cell count for control after 48 hr incubation

Co: mean cell count at the start of incubation

b: ED₅₀ was the effective dose which inhibited growth to 50% of control group




Fig. 4. The effect of pedunculagin on the growth of P388 cells. ○:control ●:1 µg/ml ▽:5 µg/ml ▼:10 µg/ml □:20 µg/ml, 5.29×10^5 cells/ml were cultured in 5% CO₂ incubator at 37°C for 48 hr, a vs b: $p < 0.05$, a vs c, d, e: $p < 0.01$ (Student's t-test), The values were given as Mean ± S.E. of n=4

there was little difference in growth ratio between the group of 10 and 20 µg/ml (Fig. 3).

Initial cell number of P388 was 5.29×10^5 cells/ml, and its ED₅₀ to pedunculagin was 2.98 µg/ml (Table I). Pedunculagin didn't show the dose-dependent cytotoxicity against P388 (Fig. 4).

Initial cell number of L1210 was 2.55×10^5 cells/ml, and its ED₅₀ to pedunculagin was 9.35 µg/ml (Table I). Pedunculagin showed the dose-dependent cytotoxicity against L1210 (Fig. 5).

Initial cell number of S180 was 5.80×10^4 cells/ml, and its ED₅₀ to pedunculagin was 1.38 µg/ml (Table I). Pedunculagin showed the dose-dependent cytotoxicity against S180. Especially growth ratio of the group of 20 µg/ml was -7.01% (Fig. 6).

Pedunculagin showed the cytotoxicity against K-562, HL-60, P388, L1210 and S180 (ED₅₀ < 10 µg/ml). HL-60 was the most sensitive (ED₅₀ = 0.92 µg/ml), and L1210 was the most insensitive (ED₅₀ = 9.35 µg/ml) to pedunculagin.

Bae *et al.* (1994) reported that bisabolangelone isolated from *Angelicae Koreanae Radix* showed the cytotoxicity against L1210 and HL-60, and ED₅₀ were 1.20 and 2.30 µg/ml respectively. Pedunculagin showed the stronger cytotoxicity against HL-60 than bisabolangelone, and the weaker cytotoxicity against L1210 than bisabolangelone.

Baik *et al.* (1993) also reported that ar-turmerone isolated from curcuma species showed the cytotoxicity against L1210, HL-60 and K-562. And, ED₅₀ were all above 10 µg/ml.




Fig. 5. The effect of pedunculagin on the growth of L-1210 cells. ○: control ●: 1 µg/ml ▽: 5 µg/ml ▼: 10 µg/ml □: 20 µg/ml, 2.55×10^5 cells/ml were cultured in 5% CO₂ incubator at 37°C for 48 hr, a vs b: $p < 0.05$, a vs c, d, e and f vs g, h, i, j: $p < 0.01$ (Student's t-test), The values were given as Mean ± S.E. of n=4




Fig. 6. The effect of pedunculagin on the growth of S-180 cells. ○: control ●: 1 µg/ml ▽: 5 µg/ml ▼: 10 µg/ml □: 20 µg/ml, 5.80×10^4 cells/ml were cultured in 5% CO₂ incubator at 37 for 48 hr, a vs b, c, d, e and f vs h, i, j: $p < 0.01$, f vs g: $p < 0.05$ (Student's t-test), The values were given as Mean ± S.E. of n=4.

Lee *et al.* (1986) reported that antitumor substances were isolated from *Lithospermum erythrorhizon*, *Curcuma domestica*, *Tricosanthes kirilowii*, *Panax ginseng* and *Liriodendron tulipifera*, and that those substances showed the cytotoxicity against L1210. And, ED₅₀ were all above 10 µg/ml.

In view of the results so far achieved, pedunculagin was regarded to have the significant cytotoxicity against K-562, HL-60, P388, L1210 and S180.

In vivo

Pedunculagin was examined for the ability of tumor immunity to host animal *in vivo* on the basis of the data shown *in vitro*. Not thinking of the metabolism *in vivo* of pedunculagin at the dose used *in vitro*, pedunculagin was administered with the doses of 50

Table II. Mean survival time and T/C ratio of each group.

Mouse	Control	50 µg/kg	100 µg/kg
MST ^a	24.83 ± 1.40	30.00 ± 0.00 ^c	30.00 ± 0.00 ^d
T/C(%) ^b	100	120.82	120.82

*a: MST=mean survival time

*b: T/C(%) = $\frac{\text{MST of Treated Group}}{\text{MST of Control Group}} \times 100$

*c,d: Significantly different from control, $p < 0.01$ (Student's t-test)

*The values were given as Mean ± S.E. of n=8





Fig. 7. The effect of pedunculagin treated on the 20th day before inoculation of 10^5 of S-180 cells on lengthening the life span in ICR mouse. ▽: control ▼: 50 µg/kg □: 100 µg/kg, The values were given as survival ratio (%) of n=6 for 30 days.

and 100 µg intraperitoneally once at 20 days before S180 inoculation. It was quite little concentration than the order of mg generally used.

In the group of 50, 100 µg/kg, one mouse was excluded from calculation, the others were not No-takes. T/C ratio of each group was 120.82 (%) equally, the dose-dependency was not shown (Table II). Pedunculagin have the effect of lengthening the life span in the mouse bearing S180 (Fig. 7).

Taking into account the dose, pedunculagin was thought to have the strong antitumor activity *in vivo*. The dose-dependency was not shown, but it was regarded that the range of concentration was so narrow. It was considered that there was no difference in the antitumor activity of pedunculagin between the dose of 50 µg and that of 100 µg. It was considered that the wide scope examinations of pedunculagin must be carried out about the antitumor activity including the route of administration, the time of administration, the sorts of tumor cell line versus host animal and the concentration of drug. As a result, pedunculagin was thought to have the strong antitumor activity by the



Scheme 1. *In vitro* assay.

single dose once 20 days before S180 inoculation which was thought to be quite long time. It was considered that the mechanism of the activity must be examined more detailly in the near future.

REFERENCES CITED

- Ahn, Y. K. and Kim, J. H., Effects of squalene on the immune responses in mice (II). *Arch. Pharm. Res.*, 15(1), 20-29 (1992).
- Anders, B. and Budgard, H., Prodrugs of 5-fluorouracil VIII improved rectal and oral delivery of 5-fluorouracil via various prodrugs. Structure-rectal absorption relationship. *Int. J. Pharm.*, 36, 41 (1987).
- Arai, Y., Tanooka, H., Sekine, T. and Fukuoka, F., Effect of immunosuppressive agents on antitumor action of lentinan. *Gann*, 62, 131-134 (1971).
- Bae, K. H., Ji, J. M., Kang, J. S. and Ahn, B. Z., A Cytotoxic Component from Angelicae Koreanae Radix against L1210 and HL-60 Cells. *Arch. Pharm. Res.*, 17, 45-47 (1994).
- Baik, K. U., Jung, S. H. and Ahn, B. Z., Recognition

- of Pharmacophore of ar-Turmerone for its Anticancer Activity. *Arch. Pharm. Res.*, 16, 254-256 (1993).
- Bodor, N. and Kaminsk, J. J., Prodrugs and site-specific chemical delivery system. *Ann. Rept. Med. Chem.*, 22, 303 (1987).
- Bomford, R. and Moren, C., Mechanism of the anti-tumor effect of glucans and fructosans: a comparison with *C. parvum*. *Br. J. Cancer.*, 36, 41-48 (1977).
- Cancer Chemotherapy National Service Center, Protocols for screening chemical agents and natural products against animal tumors and other biological systems. *Cancer Chemotherapy Reports*, 3(2), 33 (1972).
- Dipiro, J. T., Talbert, R. L., Hayes, P. E., Yee, G. C. and Posey, L. M., *Pharmacotherapy a Pathophysiological Approach*. Elsevier, Amsterdam, 1989, p.1343.
- Gali, H., Perchellet, E., Klish, D., Johnson, J. and Perchellet, J., Antitumor-promoting activities of hydrolyzable tannins in mouse skin. *Carcinogenesis*, 13, 715-718 (1992).
- Gilman, A. G., Goodman, L. S., Rall, T. W. and Murad, F., *Goodman and Gilman's the Pharmacological Basis of Therapeutics*. 7th ed., Macmillan Publishing Co., New York, 1988, p.1268.
- Gogate, U. S. and Repta, A. J., N-(Acycloxyalkoxy-carbonyl) derivatives as potential prodrugs of amines II. Esterase-catalysed release of parent amines from model prodrugs. *Int. J. Pharm.*, 40, 249 (1987).
- Han, J. H., Oh, C. H. and Eun, J. S., Effect of Glycyrrhizae Radix on the immune responses(I). *Yak-hak Hoeji*, 35(3), 154-164 (1991).
- Hyun, J. W., Studies on Antitumor Components of *Agrocybe cylindracea* [Dissertation]. Seoul: National Seoul University, 1993.
- Ikekawa, T., Nakanishi, M., Uehara, N., Chihara, G. and Fukuoka, F., Antitumor action of some basidiomycetes, especially *Phellinus linteus*. *Gann*, 59, 155-157 (1968).
- Ikekawa, T., Uehara, N., Maeda, Y., Nakanishi, M. and Fukuoka, F., Antitumor activity of aqueous extracts of edible mushrooms. *Cancer Res.*, 29, 734-735 (1969).
- Inokuchi, J., Okabe, H., Yamauchi, T., Nagamatsu, A., Nonaka, G. and Nishioka, I., Inhibition of Angiotensin-converting enzyme in crude drugs. II. *Chem. Pharm. Bull.*, 33, 264-269 (1985).
- Komatsu, N., Okubo, S., Kikumoto, S., Kimura, K., Saito, G. and Sakai, S., Host-mediated antitumor action of schizophyllan, a glucan produced by *Schizophyllum commune*. *Gann*, 60, 137-144 (1969).
- Lee, J. H., Kang, S. K. and Ahn, B. Z., Antineoplastic Natural Products and the Analogues (XI). *Kor. J. Pharmacogn.*, 17, 286-291 (1986).

- Lee, K. H., Kashiwada, Y., Nonaka, G., Nishioka, I., Nishizawa, M., Yamagishi, T., Bodner, A. J., Kilkuskie, R. E. and Cheng, Y. C., Natural products as antiviral agents, Chu, C. K. and Cutler, H.G. (Eds.), *Tannins and Related Compounds as anti-HIV Agents*, Plenum Press, New York, 1992, pp.69-90.
- Lyu, K. S., Han, D. S., Yoo, S. B., Jung, B. S. and Sung, C. G., *Natural Products Chemistry*, Yung Lim Publish Co., Seoul, 1989, pp.228-229.
- Maeda, Y. Y., Hamuro, J. and Chihara, G., The mechanisms of action of anti-tumor polysaccharides I. *Int. J. Cancer.*, 8, 41-46 (1971).
- Mazer, N. A., Anderson, J. M. and Kim, S. W., *Advances in Drug Delivery Systems(4)-Pharmacokinetic and Pharmacodynamic Aspects of Polypeptide Delivery*, Elsevier, Amsterdam, 1990, p. 343.
- Miyamoto, K., Murayama, T., Nomura, M., Hatano, T., Yoshida, T., Furukawa, T., Koshiura, R. and Okuda, T., Antitumor activity and interleukin-1 induction by tannins. *Anticancer Res.*, 13, 37-42 (1993a).
- Miyamoto, K., Nomura, M., Murayama, T., Furukawa, T., Hatano, T., Yoshida, T., Koshiura, R. and Okuda, T., Antitumor activities of ellagitannins against sarcoma-180 in mice. *Biol. Pharm. Bull.*, 16, 379-387 (1993b).
- Miyamoto, K., Nomura, M., Sasakura, M., Matsui, E., Koshiura, R. Murayama, T., Furukawa, T., Hatano, T., Yoshida, T. and Okuda, T., Antitumor activity of oenothien B, a unique macrocyclic ellagitannin. *Jpn. J. Cancer. Res.*, 84, 99-103 (1993c).
- Nonaka, G., Nishioka, I., Nishizawa, M., Yamagishi, I., Kashiwada, Y., Dutschman, G. E., Bodner, A. J., Kilkuskie, R. E., Cheng, Y. C. and Lee, K. H., Anti-AIDS agents, 2: inhibitory effects of tannins on HIV replication in H9 lymphocyte cells. *J. Nat. Prod.*, 53, 587-595 (1990).
- Serit, M., Okubo, T., Hagiwara, N., Kim, M. J., Nonaka, G., Nishioka, I. and Yamamoto, T., Comparative antibacterial activity of quercitol gallates. *Agric. Biol. Chem.*, 55, 1893-1894 (1991).
- Shibutai, S., Nagasawa, T., Oura, H., Nonaka, G. and Nishioka, I., Mechanism of the blood urea nitrogen decreasing activity of rhatannin from Rhei rhizoma in rat. *Chem. Pharm. Bull.*, 31, 2378-2385 (1983).
- Shirahata, S., Murakami, H., Nishiyama, K., Sugata, I., Shinogara, K., Nonaka, G., Nishioka, I. and Omura, H., DNA breakage by hydrolyzable tannins in the presence of cupric ion. *Agric. Biol. Chem.*, 49, 1033-1040 (1985).
- Shirahata, S., Murakami, H., Nishiyama, K., Yamada, K., Nonaka, G., Nishioka, I. and Omura, H., DNA breakage by Flavan-3-ols and procyanidins in the presence of cupric ion. *J. Agric. Food Chem.*, 37, 299-303 (1989).
- Thayer, P.S., Himmerlfarb, P. and Watts, G.L., Cytotoxicity assay with L1210 cell *in vitro*, Comparison with L1210 *in vitro* and KB cells *in vitro*. *Cancer Chem. Rep.*, 2, 1-25 (1971).
- Torikai, T., Itoh, O., Toyoshima, S. and Osawa, T., Purification and biological activities of a mouse serum protein increased by administration of streptococcal preparation, OK-432. *Gann*, 69, 657-665 (1978).
- Uchida, S., Edamatsu, R., Hiramatsu, M., Mori, A., Nonaka, G., Nishioka, I., Niwa, M. and Ozaki, M., Condensed tannins scavenge active oxygen free radicals. *Med. Sci. Res.*, 15, 831-832 (1987).
- Uchida, S., Ikare, N., Ohta, H., Niwa, M., Nonaka, G., Nishioka, I. and Ozaki, M., Inhibitory effects of condensed tannins on angiotensin converting enzyme. *Jpn. J. Pharmacol.*, 43, 242-246 (1987).
- Ueki, S., Nishioka, I., Fujiwara, M. and Nonaka, G., Psychotropic effects of rhubarb. *Gendaitoyoigaku*, 7, 98-103 (1986).
- Yoshida, T., Chou, T., Matsuda, M., Yasuhara, T., Yazaki, K., Hatano, T., Nitta, A. and Okuda, T., Woodfordin D and oenothien A, trimeric hydrolyzable tannins of macro-ring structure with antitumor activity. *Chem. Pharm. Bull.*, 39, 1157-1162 (1991).
- Yoshiki, K., Nonaka, G., Nishioka, I., Chang, J. J. and Lee, K. H., Antitumor agents, 129 tannins and related compounds as selective cytotoxic agents. *J. Nat. Prod.*, 55, 1033-1043 (1992).
- Yukio Akiyama, Junji Hamuro., Effect of antitumor polysaccharides on specific and nonspecific immune responses and their immunological characteristics. *Protein, Nucleic Acid and Enzyme.*, 26, 208-224 (1981).
- Zahang, J., Chihara, G. and Facht, J., Effect of lentinan on tumor growth in murine allogeneic and syngeneic hosts. *Int. J. Cancer.*, 25, 371-376 (1980).